FTC sues to block Amgen's $27.8 bln deal for Horizon Therapeutics -statement

Horizon Therapeutics

16/05/2023 15:50

WASHINGTON, May 16 (Reuters) - The U.S. Federal Trade
Commission said on Tuesday that it would sue to stop Amgen Inc's
 AMGN.O  $27.8 billion deal to buy Horizon Therapeutics Plc
 HZNP.O .
    The deal, which was announced in December 2022, would give
Amgen two fast-growing drugs, the thyroid eye disease treatment
Tepezza and gout treatment Krystexxa. Amgen hopes they can act
as a bulwark against competition for its blockbuster arthritis
drug Enbrel. 
    Furthermore, other key drugs in its portfolio, such as
psoriasis therapy Otezla, face loss of patents over the next few
years.
    

 (Reporting by Diane Bartz; editing by Tim Ahmann)
 ((Rami.Ayyub@thomsonreuters.com;))